Usage instructions:
Dosage and directions for use: Vi-Daylin® drops will not curdle milk and may be added to infants' feeds or may be mixed with cereal or fruit juice, or may be taken as is. Daily dosage for babies 1-12 months: 0.6 ml orally or as directed by the doctor.

Storage instructions:
Store in a cool (below 25 degrees C) place. Protect from light.

Warnings:
Contra-indications: Vi-Daylin® drops are contra-indicated in patients hypersensitive to any of the ingredients. Not intended for patients where specific vitamin deficiency exists. Keep this product out of the reach of children. In cases of accidental overdose, call a doctor or seek medical advice immediately. Women who are, or might become pregnant should avoid taking daily supplements containing more than 5000 IU vitamin A, without consulting a medical practitioner. The safe dosage may be exceeded when medicines and/or health products containing vitamin A are taken together with a high dietary intake of vitamin A. Side-effects and special precautions: Side-effects: Allergic reactions, including rash, pruritus, and anaphylaxis have been reported with vitamin use. Components of these products have been associated with gastrointestinal effects such as heartburn, eructation, abdominal pain and cramps, diarrhoea, constipation, vomiting, nausea and anorexia. Deterioration of acneiform vulgaris, or eruption of acneiform exanthema, has been noted with several components. Bright yellow urine discoloration has been reported with riboflavine usage. Long term administration of vitamin A>10 000 IU daily may cause chronic hypervitaminosis A. symptoms of chronic intoxication are as follows: headache, vertigo, hyperkeratosis, changes in skin and mucous membranes, tenderness and pain in the bone and joints, fever, increased serum cholesterol and serum triglyceride concentration, intracranial hypertension, fatigue, hypercalcaemia, hyperglycaemia, increased alkaline phosphatase, hypoproteinaemia, hypoprothrombinaemia, low serum ascorbic acid, decreased protein content of the cerebrospinal fluid, elevated urinary hydroxyproline and hypercalciuria, polyuria, increased frequency of micturition, urinary incontinence, enuresis and acute renal failure due to tubular necrosis, papilledema, dryness, haemorrhages and fissures of the lips, yellow to yellow-orange discolouration of the skin, decreased tolerance to sunlight, changes in pigmentation, hair loss and brittle nails, spider angiomas and oedema. Prolonged moderate intake of vitamin A (20 000 IU per day), when taken over prolonged periods of time can cause significant hepatic injury, including cirrhosis. Total cumulative dose may be a critical factor. Characteristic features of chronic vitamin D intoxication include hypercalcemia and deposition of calcium salts in various tissues. Occasionally, mental disturbances, cerebella ataxia, peripheral facial paresis, apathy, and lack of interest have been reported. Precautions: Caution should be used in patients with chronic liver disease and in patients with hyperlipidemia. Vitamin D should be used with caution in patients with hypercalcaemia. Increased sensitivity to vitamin D is observed in patients with renal impairment and having an abnormal calcium/phosphorus ratio. Drug interactions: The effects of vitamin D may be reduced in patients taking barbiturates or anti-convulsants due to accelerated metabolism of vitamin D. Known symptoms of overdosage and particulars of its treatment: High doses of individual components of this product have been associated with eczematous and exanthematous skin lesions, fatigue, and insomnia. In higher niacinamide doses, liver damage, gout and ulcer formation have been noted. High doses of vitamin A can lead to haemolysis, anaemia, neutropenia, leukocytosis, thrombocytopenia, aplastic anaemia, increased sedimentation rate, and accelerated reabsorption of trabecular and cortical bone. Initial symptoms of vitamin D overdose are usually comprised of weakness, lassitude, headache, nausea, vomiting and diarrhoea. Renal function can be impaired at an early stage with polyuria, polydipsia, nocturia, decreased urinary concentrating ability and proteinuria. If symptoms of overdosage arise, discontinue use of the medicine. Treatment is symptomatic and supportive. Keep out of reach of children.

Information not available.